Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

This is a single center, single arm, open label phase I study to demonstrate the feasibility
of manufacturing CAR-T cells expressing tandem receptors against both CD20 and CD19
(CAR-20/19-T) in a completely closed system using the CliniMACS Prodigy device and then
determine the safety of this dual targeted CAR in a first-in-human study of patients with
relapsed and refractory B cell malignancies. Secondary outcomes will include response rates,
and observed toxicities of the treatment, specifically the development of cytokine release
syndrome (CRS), an inflammatory storm that has been seen with previous CAR-T therapies.

Inclusion Criteria

1. Diagnosis of B-cell NHL or CLL/SLL: Patients must be aged≥18 years and ≤70 years with
relapsed, refractory disease and no available curative options that meet clinical
criteria to initiate treatment.

2. Patients with B-cell NHL or CLL/SLL must have either CD19 or CD20 positive disease on
most recent biopsy performed (a repeat biopsy is not mandatory for this study). A
minimum of 5% CD19 or CD20 positivity by immunohistochemistry on prior or repeat
biopsy is required.

3. Absolute CD3+ T cell count ≥100/mm3

a. Patients who receive chemotherapy and/or steroids after CD3+ T-cell count, but
before apheresis, will require this test to be repeated.

4. MRI brain without evidence of CNS involvement

5. Lumbar puncture with CSF analysis by cytology and flow cytometry in patients with
prior history of CNS disease. For patients without a history of CNS positive disease,
a negative MRI of the brain will suffice.

6. Measurable disease must have been documented within 4 weeks of the time of consent
defined as the following by disease specific subtype:

1. B-cell NHL: Active disease defined as nodal lesions greater than 20 mm in the
long axis or extranodal lesions >10 mm in long and short axis or bone marrow
involvement that is biopsy proven

2. CLL/SLL: Active disease by either bone marrow, peripheral flow cytometry, or CT
and/or PET imaging with nodal disease

7. Patients should have failed at least two lines of a standard treatment and meet
disease specific criteria detailed below:

1. CLL/SLL: measurable disease as defined above that has relapsed after at least one
line of chemo-immunotherapy and progressed or intolerant to ibrutinib monotherapy

2. CD19 or CD20 positive B cell NHL limited to the following histologies: Advanced
Stage III or IV Follicular Lymphoma, Diffuse Large B cell Lymphoma (de novo or
transformed), and Mantle cell lymphoma. Specific criteria include:

- Patients must have progressed after two lines of cytotoxic chemotherapy of
which one must be anthracycline containing.

- Must have received Rituximab or another CD20 antibody and at minimum two
chemotherapy regimens appropriate for their disease.

- Either failed autologous transplant or ineligible to receive autologous
transplant

8. Karnofsky performance score ≥70. See Appendix A for scales.

9. Normal Baseline Neurological Evaluation: Mini-Mental Status Exam Score 24-30 (Appendix
B)

10. Adequate hepatic function, defined as AST and ALT <3 x upper limit of normal (ULN);
serum bilirubin and alkaline phosphatase <2 x ULN, or considered not clinically
significant as per the clinical PIs discretion (e.g. Gilbert's or indirect
hyperbilirubinemia) or felt to be due to underlying disease.

11. Adequate renal function, defined as creatinine clearance>60 ml/min

12. Able to provide written informed consent

13. Agree to practice birth control during the study

14. Adequate cardiac function as indicated by New York Heart Association (NYHA)
classification I or II AND left ventricular ejection fraction of ≥40% (by cardiac ECHO
or MUGA) and adequate pulmonary function as indicated by room air oxygen saturation of
≥92%.

15. Expected survival >12 weeks

16. Negative urine or serum pregnancy test in females of child bearing potential at study
entry and again within 48 hours' prior lymphodepleting chemotherapy.

17. Patients with prior blinatumomab treatment require repeat biopsy post-blinatumomab
treatment that demonstrates CD19 or CD20 positive disease.

18. Meet criteria for regarding fertility and contraception detailed in section 4.4

19. Central line access will be required for CAR-20/19-T cell infusion.

Exclusion Criteria

1. Positive beta-HCG in female of child-bearing potential defined as per table 1.

2. Patients with known systemic allergy to bovine or murine products.

3. Known prior positive serology for human anti-mouse antibody (HAMA).

4. Confirmed active human immunodeficiency virus (HIV), Hepatitis B or C infection.

5. History of significant autoimmune disease OR active, uncontrolled autoimmune
phenomenon: such as systemic lupus erythematous, Wegner's glomerulonephritis,
autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura (AIHA, ITP) requiring
steroid therapy defined as >20 mg of prednisone.

6. Presence of ≥grade 3 non-hematologic toxicities as per CTCAE version 5.0 from any
previous treatment unless it is felt to be due to underlying disease.

7. Concurrent use of investigational therapeutic agents or enrollment on another
therapeutic clinical trial at any institution. Minimum of ≥4 weeks required from
administration of any other investigational agents on other clinical trials prior to
enrollment on this CAR-T protocol.

8. Refusal to participate in the long-term follow-up protocol

9. Patients with active CNS involvement by malignancy on MRI or by lumbar puncture.

a. Patients with prior CNS disease that has been effectively treated will be eligible
providing treatment was >4 weeks before enrollment and a remission documented within 8
weeks of planned CAR-T cell infusion

10. Previous recipients of allogeneic hematopoietic stem cell transplantation (AHCT) are
excluded if they are <100 days' post-transplant, have evidence of active
graft-versus-host-disease (GVHD) of any grade, or are currently on immunosuppression.

11. Previous CAR-T cell therapy directed at either CD19 or CD20 within 100 days of planned
CAR-20/19-T cell infusion) does not include re-enrollment)

12. Anti-CD20 antibody treatment within 4 weeks of cell infusion

13. Anti-CD19 antibody treatment within 4 weeks of cell infusion

14. Cytotoxic chemotherapy other than lymphodepletion within 14 days of CAR-T cell
infusion

15. Cytotoxic chemotherapy treatment within 14 days or steroid treatment (other than
replacement dose steroids) within 7 days prior to apheresis collection for CAR-T cells

16. Patients post solid organ transplant who develop high grade lymphomas or leukemias

17. Concurrent active malignancy (exceptions: treated solid malignancy in >2 years'
remission, treated basal or squamous cell carcinomas of the skin)

Special Criteria for regarding Fertility and Contraception

Female subjects of reproductive potential (women who have reached menarche or women who
have not been post-menopausal for at least 24 consecutive months, i.e., who have had menses
within the preceding 24 months, or have not undergone a sterilization procedure
[hysterectomy or bilateral oophorectomy]) must have a negative serum or urine pregnancy
test performed as part of eligibility criteria and again within 48 hours of initiation of
lymphodepleting chemotherapy.

Due to the high-risk level of this study, while enrolled, all subjects must agree not to
participate in a conception process (e.g., active attempt to become pregnant or to
impregnate, sperm donation, in vitro fertilization). Additionally, if participating in
sexual activity that could lead to pregnancy, the study subject must agree to use reliable
and double barrier methods of contraception during the follow-up period of the protocol.

Acceptable birth control includes a combination of two of the following methods:

- Condoms* (male or female) with or without a spermicidal agent.

- Diaphragm or cervical cap with spermicide

- Intrauterine device (IUD)

- Hormonal-based contraception Subjects who are not of reproductive potential (women who
are premenarche or have been post-menopausal for at least 24 consecutive months or
have undergone hysterectomy tubal ligation, salpingectomy, and/or bilateral
oophorectomy or men who have documented azoospermia) are eligible without requiring
the use of contraception.